<DOC>
	<DOCNO>NCT03009799</DOCNO>
	<brief_summary>This clinical investigation aim demonstrate NCX-4240 effective safe decrease number day adenoviral conjunctivis detect eye reduce duration and/or severity sign symptom adenoviral conjunctivis</brief_summary>
	<brief_title>Efficacy Safety Iota-Carrageenan Eye Drops ( NCX-4240 )</brief_title>
	<detailed_description>A multicenter , double mask , parallel , randomize 1:1 ratio clinical investigation compare carrageenan eye drop ( NCX 4240 ) versus placebo 21 day . Total expected number patient : 148 Randomization : patient randomize 1:1 : - Group A : eye drop contain iota-carrageenan ( NCX 4240 ) , 1 drop eye 8 times/day 7 day ( mandatory ) least 4 8 times/day next 14 day Day 21 - Group B : ocular lubricant eye drop ( carmellose 0.5 % sterile solution ) 1 drop eye 8 times/day 7 day ( Mandatory ) , 4 8 times/day next 14 day Day 21 .</detailed_description>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Inclusion</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<mesh_term>Carboxymethylcellulose Sodium</mesh_term>
	<criteria>With unior bilateral acute adenoviral conjunctivis diagnostised adenoplus test Conjunctivis sign symptoms least one eye AND positive adenoplus test least one eye whatever signs/symptoms positive adenoplus test eye Negative result adenoplus test eye suspect bacterial , fungal , herpes , chlamydia acanthamoeba coinfection , base clinical investigation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>adenoviral conjunctivis</keyword>
	<keyword>iota-carrageenan</keyword>
</DOC>